Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

India’s Sun Pharmaceutical Industries has reached an agreement to acquire U.S.-listed Organon & Co (NYSE:OGN) in an all-cash ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The average one-year price target for Organon (NYSE:OGN) has been revised to $11.02 / share. This is an increase of 25.58% from the prior estimate of $8.77 dated April 25, 2026. The price target is an ...

In the latest close session, Organon (OGN) was down 1.87% at $9.46. This change lagged the S&P 500's 0.01% loss on the day. Meanwhile, the Dow lost 0.32%, and the Nasdaq, a tech-heavy index, added ...

The most recent trading session ended with Organon (OGN) standing at $20.18, reflecting a +1.05% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily ...

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies ...

Looking ahead to 2030, our model projects OGN could trade at an average price of $27.41, with a potential range between $20.56 and $34.27. This represents a potential 105.5% return from today's price.

Organon & Co. (NYSE:OGN) is one of the 10 High-Flying Stocks With Double-Digit Returns. Organon bounced back by 30.93 percent on Friday to close at $11.26 apiece, as investors snapped up shares ...